Expensive exams benefiting medical boards

Nonprofit medical boards reported a $23 million surplus in 2013, more than triple what was recorded a decade earlier. Most of that revenue comes from charging physicians for certification exams.

In a research letter published in JAMA, plastic surgeons Brian Drolet, MD, of Vanderbilt University Medical Center and Vickram Tandon, MD, of the University of Michigan, examined the most recently published tax documents, from fiscal year 2013, for the 24 members of the American Board of Medical Specialties. They also compiled what fees were charged for initial certification and maintenance of certification (MOC) as of March 2017.

The mean fee for 2017 was $1,846 for an initial written exam and $1,694 for an initial oral exam. 19 boards offered subspecialty verification at the mean cost of $2,060. For MOC fees, the mean cost was $257 annually.

Some of the highest fees within specialties included:

  • Allergy and immunology ($3150 application/written exam fee, $150 MOC annual fee).
  • Internal medicine ($1,365 written exam fee, $2,200-$2,830 subspecialty fee, $194-$256 MOC annual fee).
  • Otolaryngology ($3,580 written exam fee, $$1,800 oral exam fee, $2,485-$4,825 subspecialty fee, $310 MOC annual fee).
  • Radiology ($2,560 written exam fee, $3,270 subspecialty fee, $340 MOC annual fee).

The lowest fees were paid by emergency physicians and orthopedic surgeons.

Boards made the bulk of their revenue—88 percent—off these exams and MOC fees. The cost of administering the exams, however, accounts for about 20 percent of their annual expenses, which Drolet and Tandon wrote goes against the “fiduciary responsibility” of these nonprofit organizations to “match revenues and expenditures.”

“Board certification should have value as a meaningful educational and quality improvement process,” they wrote. “Although some evidence suggests board certification may improve performance and outcomes, the costs to physicians are substantial. More research is needed to assess the cost-benefit balance and to demonstrate value in board certification.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.